【摘要翻译】人前列腺癌的雄激素受体基因突变
这个帖子发布于 20 年零 337 天前，其中的信息可能已发生改变或有所发展。
[文题]ANDROGEN RECEPTOR GENE MUTATIONS IN HUMAN PROSTATE CANCER
人前列腺癌的雄激素受体基因突变
[来源]J Steroid Biochem. Molec. Biol.
[年、卷、期、页]Vol. 46, No. 6, pp. 759--765, 1993
[作者]HIROYOSHI SUZUKI, NAOHIDE SATO, YOSHIO WATABE, MOTOYUKI MASAI, SUSUMU SEINO and JUN SHIMAZAKI
[原文摘要]
Summary To investigate the structural abnormality of the androgen receptor (AR) in human prostate cancers,exons B--H encoding DNA and hormone-binding domains were examined by single-strand conformation polymorphism analysis of polymerase chain reaction products using originally designed oligoprimers. Tissues from 7 cases of untreated stage B prostate cancer surgically removed and from 8 cases of endocrine therapy resistant cancers obtained at autopsy were used in the study. Two different mutations were identified in exons D and H in the different cancer foci of the same cancer death patient. One mutation in exon D (at codon 701, Leu to His) was detected in the prostate, and the other in exon H (at codon 877,Thr to Ala) was found in metastatic tissues. In untreated cancer tissues and the other autopsy samples, no mutations were detected. The mutation in exon H was identical to that reported in LNCaP cells. These results indicate that AR gene mutations occur in relation to endocrine therapy-resistance, although the mutation was found in 1 out of 8 resistant cases (12.5%) at autopsy.
[中文摘要]
摘要：目的是用自己设计的寡聚引物进行聚合酶链反应而得到的产物去通过单链构象多肽性进行分析，检测外显子B-H编码的DNA和激素结合区，来研究人前列腺癌的雄激素受体结构的异常。在这个研究中组织来源是7例来自外科切除未治疗的B期的前列腺癌和8例内分泌治疗耐药后的组织活检。在因相同癌死亡的病人的不同癌中心中的AR的外显子D和H有二种突变已经被证实。一个突变是在前列腺的外显子D中（在密码子701，Leu到His）被发现，另一个是在转移组织的外显子Ｈ中（在密码子877,Ｔｈｒ到Ａｌａ）被发现。在未治疗的癌组织中和别的活检样本中没有突变被发现。在关于LNCaP细胞系的报道中外显子Ｈ中的突变已被证明，虽然这些突变在１２．５％的活检耐药病例中被发现，但这些结果提示ＡＲ基因的突变发生于内分泌治疗耐药相关。
请指教，谢谢！
人前列腺癌的雄激素受体基因突变
[来源]J Steroid Biochem. Molec. Biol.
[年、卷、期、页]Vol. 46, No. 6, pp. 759--765, 1993
[作者]HIROYOSHI SUZUKI, NAOHIDE SATO, YOSHIO WATABE, MOTOYUKI MASAI, SUSUMU SEINO and JUN SHIMAZAKI
[原文摘要]
Summary To investigate the structural abnormality of the androgen receptor (AR) in human prostate cancers,exons B--H encoding DNA and hormone-binding domains were examined by single-strand conformation polymorphism analysis of polymerase chain reaction products using originally designed oligoprimers. Tissues from 7 cases of untreated stage B prostate cancer surgically removed and from 8 cases of endocrine therapy resistant cancers obtained at autopsy were used in the study. Two different mutations were identified in exons D and H in the different cancer foci of the same cancer death patient. One mutation in exon D (at codon 701, Leu to His) was detected in the prostate, and the other in exon H (at codon 877,Thr to Ala) was found in metastatic tissues. In untreated cancer tissues and the other autopsy samples, no mutations were detected. The mutation in exon H was identical to that reported in LNCaP cells. These results indicate that AR gene mutations occur in relation to endocrine therapy-resistance, although the mutation was found in 1 out of 8 resistant cases (12.5%) at autopsy.
[中文摘要]
摘要：目的是用自己设计的寡聚引物进行聚合酶链反应而得到的产物去通过单链构象多肽性进行分析，检测外显子B-H编码的DNA和激素结合区，来研究人前列腺癌的雄激素受体结构的异常。在这个研究中组织来源是7例来自外科切除未治疗的B期的前列腺癌和8例内分泌治疗耐药后的组织活检。在因相同癌死亡的病人的不同癌中心中的AR的外显子D和H有二种突变已经被证实。一个突变是在前列腺的外显子D中（在密码子701，Leu到His）被发现，另一个是在转移组织的外显子Ｈ中（在密码子877,Ｔｈｒ到Ａｌａ）被发现。在未治疗的癌组织中和别的活检样本中没有突变被发现。在关于LNCaP细胞系的报道中外显子Ｈ中的突变已被证明，虽然这些突变在１２．５％的活检耐药病例中被发现，但这些结果提示ＡＲ基因的突变发生于内分泌治疗耐药相关。
请指教，谢谢！
回复收藏点赞
